Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoir And More

Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted

Psychedelics companies Cybin Inc. CYBN and Small Pharma Inc. DMTTF have completed their August acquisition agreement. Following their arrangement plan under the BC Business Corporations Act, and pursuant to the agreement’s terms, Small Pharma is now a wholly-owned subsidiary of Cybin. Read all the details HERE.

Meanwhile, the new combined company’s deuterated psychedelics programs has recently received two patent grants from the United States Patent and Trademark Office (USPTO,) and one from the European Patent Office (EP.) Learn more about the new IP protections HERE. 

Elon Musk And Vivek Ramaswamy Warn Of WW III In Discussion About Ukraine, Russia, China & Peace

Vivek Ramaswamy, the only major Republican presidential candidate to publicly support legalizing marijuana and moving toward regulating access to certain psychedelics, is not unlike his friend and supporter Tesla TSLA CEO Elon Musk who has also been forthcoming about psychedelic drugs and their benefits. 

Though Ramaswamy bounded into national recognition following the recent Trump-less debates, the 38-year-old tech entrepreneur has not been outspoken at those debates about his support for cannabis policy reform, unlike Musk, who has said psychedelics should be seriously considered for therapeutic uses. Keep reading HERE.

Britney's Memoir Decoded: Drugs, Depression And Drama With Timberlake

It isn't every day that the veil is lifted off a global superstar's life, revealing vulnerable crevices and raw emotions, especially not from the "Princess of Pop," Britney Spears. Her memoir, "The Woman in Me," is a treasure trove of disclosures, rendering insights into the tumultuous ride she experienced under the glaring limelight.

Pop culture aficionados would recall the iconic shaved head, the umbrella rage and the infamous paparazzi moments. However, Britney's story wasn't just about public meltdowns. At the heart of her narrative lies a battle with personal demons, exacerbated by the relentless scrutiny she faced. Read more HERE.

Who's Shaping The Psychedelic Future? Your Vote Can Decide Who Wins This Awards Show

The Third Annual Wonderland Awards to be held on November 9, 2023, in Miami will honor the brightest luminaries in the worlds of psychedelics, mental health and longevity research. In an industry abuzz with innovation, these awards distinguish those who are revolutionizing mental health and transformative practices, spotlighting visionaries and transformative organizations.

One name that stands out among this year's nominees is Javier Hasse. Noted for his expertise in the cannabis, hemp, CBD and psychedelics sectors, Hasse serves as the head of content for Benzinga and CEO of El Planteo, the most-read cannabis and psychedelics news sources in the globe and the Spanish-speaking world, respectively. He also covers psychedelics-related topics in his senior column on Forbes. With a publication list boasting over 5,000 unique articles in international media, his journalistic footprint is undeniable. But it’s not just his journalism that garners attention, Hasse’s diverse talents range from being a published photographer to a Billboard-charting rapper, collaborating with music industry stalwarts such as Wu-Tang Clan's RZA. Find out more HERE. 

The Milestone Round

• Beckley Waves has acquired ketamine therapy provider Nue Life.

• Red Light Holland’s TRUFF subsidiary granted U.S. patent for 3D movement data, more AI innovation ahead.

• Psychedelics decriminalization in California: Eureka City Council latest to pass resolution.

• Honoring Johns Hopkins psychedelic pioneer Dr. Roland Griffiths and his legacy in healing minds.

• 'I don't take drugs; Hunter S. Thompson tried everything:' Ralph Steadman on his friendship with 'Fear and Loathing in Las Vegas' star.

• Roll The Psychedelic Dice In Vegas At reMind's Business Forum This November

• Payton Nyquvest’s view on off-label markets.

• EXCLUSIVE: Becoming compliant in today's legal psychedelics markets with Allay Consulting.

• Meet NANA, the digital platform guiding and integrating psychedelic therapies by Argentina's Flor Bollini.

• Yoga and cannabis: A mindful connection, new study reveals.

See Also: Last Week's Edition Of 'Psyched'

Psychedelics ETF Weekly Performance

AdvisorShares Psychedelics ETF PSIL opened Monday, Oct. 23 at $1.41, confirming the descending opening trend as of prior weeks’ openings at $1.5, $1.54, $1.62 and $1.68.

On Friday 27, it closed at $1.41, slightly up from Friday 20’s close at $1.4, yet still below all other immediately prior closings at $1.5, $1.53 and $1.61.

Week’s highest was $1.44 on Monday 23, also confirming a descending trend here as per prior weeks’ highests $1.53, $1.60, $1.64 and $1.76, respectively. 

Week’s lowest was $1.35 both on Wednesday 25 and Thursday 26. It’s also lower than prior weeks’ lowest points at $1.40, $1.49, $1.51 and $1.61, respectively.

The ETF’s yearly price range is now between $2.54 and $1.34 (vs. last week when lowest was set at $1.41.)

Highest Trading Psychedelics Stocks Friday, Oct. 27 At Close

• GH Research GHRS closed at $6.91, lower than prior weeks’ closings at $7.28, $8.08, $8.70 and $10.05, respectively.

• COMPASS Pathways CMPS closed at $5.28, down from prior closings at $5.79, $5.99, $6.88 and $7.40.

• Mind Medicine (MindMed) MNMD closed at $2.47, down from prior closings at $2.62, $2.8, $3.09 and $3.13.

• Enveric Biosciences ENVB closed at $1.8, below prior weeks’ closings at $2.00, $2.13, $2.24 and $2.38.

• Bright Minds Biosciences DRUG closed at $1.4, down from all immediately prior closings at $1.51, $1.56, $1.47 and $1.6, respectively.

• Silo Pharma SILO closed at $1.34, slightly under prior week’s closing at $1.36, and behind former closings at $1.51, $1.66 and $1.67, respectively.

• Atai Life Sciences ATAI closed at $1.06, down from prior weeks’ closings at $1.3, $1.28, $1.39 and $1.29.

• Incannex Healthcare IXHL closed at $0.99, up from prior week’s close at $0.91, yet still down from former weeks’ closings at $1.00, $1.09 and $1.14.

• FSD Pharma HUGE closed at $0.98, down from the $1.00 threshold and falling as per prior weeks’ closings at $1.11, $1.15, $1.2 and $1.21, respectively.

• Cybin Inc. CYBN closed at almost $0.62, considerably up as of all recent prior closings at $0.48, $0.58, $0.56 and $0.53, respectively.